H.C. Wainwright reiterates Korro Bio stock rating on trial dosing

Markets Investing.com By Investing.com 06 Oct 2026 11:50 1 min read
H.C. Wainwright reiterates Korro Bio stock rating on trial dosing

Covered in this story

What has happened since

  • Korro Bio Inc is down 13.0% since this was published, 10 days ago.

Price move measured from the close nearest publication to the latest quote.

Tracked from this story

H.C. Wainwright’s $15 target on $KRRO is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.

H.C. Wainwright’s track record →

Call it yourself

No member calls on $KRRO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Korro Bio Inc →
Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.